Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 10:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 130 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Intranasal oxytocin Clear all
Completed Phase 2 Interventional Results available

The Effects of Oxytocin in Obese Adults

NCT03043053
View directory record Official record
Conditions
Obesity
Interventions
oxytocin nasal spray, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Sep 30, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

Oxytocin to Treat PTSD

NCT04228289
View directory record Official record
Conditions
PTSD
Interventions
Oxytocin, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
San Francisco, California • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 30, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress

NCT02742532
View directory record Official record
Conditions
Alcohol Use Disorder, Stress Disorders, Post-Traumatic, Anxiety Disorders, Substance Use Disorders
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
Jennifer Mitchell
Other
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 30, 2026, 10:47 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Oxytocin and Learning for Teaching

NCT02393443
View directory record Official record
Conditions
Social Psychology
Interventions
Intranasal oxytocin, Intranasal placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 30 Years
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Sep 30, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain

NCT07053774
View directory record Official record
Conditions
Pain, Acute
Interventions
Intravenous oxytocin, Intravenous placebo, Intranasal oxytocin, Intranasal placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 30, 2026, 10:47 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effects of Oxytocin on Startle Hyperreactivity in Patients With AUD and PTSD

NCT02469259
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, Alcoholism
Interventions
Oxytocin, Placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Sep 30, 2026, 10:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Intranasal Oxytocin and Maternal Neglect

NCT02737436
View directory record Official record
Conditions
Maternal Behavior
Interventions
Intranasal Oxytocin, Placebo, Functional MRI scanning
Drug · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
20 Years to 45 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2019
U.S. locations
2
States / cities
Iowa City, Iowa • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Sep 30, 2026, 10:47 AM EDT
Completed Not applicable Interventional Results available

Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia?

NCT01312272
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Inactive placebo nasal spray
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Sep 30, 2026, 10:47 AM EDT
Completed Phase 3 Interventional Results available

A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder

NCT02985749
View directory record Official record
Conditions
Autism Spectrum Disorder, Pervasive Developmental Disorder, ASD, PDD
Interventions
Intranasal Oxytocin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years to 55 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Sep 30, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

Single Dose Intranasal Oxytocin and Cognitive Effects in Autism

NCT02493426
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Intranasal Oxytocin, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
5 Years to 40 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2023 · Synced Sep 30, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

Stimulant Oxytocin Study

NCT03016598
View directory record Official record
Conditions
Stimulant Use & Co-occuring Opioid Use Disorders
Interventions
Intranasal oxytocin, Intranasal placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Sacramento, California • San Francisco, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 30, 2026, 10:47 AM EDT
Recruiting Phase 2 Interventional

A Study of the Effects of Oxytocin in Adults With Binge-eating Disorder

NCT05664516
View directory record Official record
Conditions
Binge-eating Disorder
Interventions
TNX-1900 (Tonix Pharmaceuticals), Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Sep 30, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome

NCT01254045
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
placebo, oxytocin 24IU, oxytocin 48IU
Drug
Lead sponsor
Stanford University
Other
Eligibility
13 Years to 29 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Sep 30, 2026, 10:47 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Intranasal Oxytocin Intervention for Caregivers to Persons With Dementia

NCT06364228
View directory record Official record
Conditions
Stress
Interventions
Placebo, Oxytocin Intranasal Spray 12 International Unit (12IU), Oxytocin Intranasal Spray 24 International Unit (24IU), Functional MRI
Drug · Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
50 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 30, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

Oxytocin and Social Cognition in Schizophrenia

NCT00884897
View directory record Official record
Conditions
Social Cognition, Social Anxiety, Emotional Intelligence
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Sep 30, 2026, 10:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dyad Oxytocin Study (DOS)

NCT02302209
View directory record Official record
Conditions
Schizophrenia, Autism Spectrum Disorder
Interventions
Oxytocin, Placebo Comparator
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Sep 30, 2026, 10:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Intranasal Oxytocin and Enhancement of Team Cohesion

NCT02302430
View directory record Official record
Conditions
Unit Cohesion
Interventions
Oxytocin, Placebo comparator
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 28 Years
Enrollment
486 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Sep 30, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

Inhaled Oxytocin and HPA Axis Reactivity

NCT03593473
View directory record Official record
Conditions
Depression, Postpartum, Anxiety Disorders, Stress, Psychological
Interventions
Intranasal Oxytocin, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Sep 30, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

Intranasal Oxytocin Treatment for Social Deficits in Children With Autism

NCT01624194
View directory record Official record
Conditions
Autism
Interventions
Oxytocin nasal spray, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
6 Years to 12 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 30, 2026, 10:47 AM EDT
Completed Phase 1 Interventional

Oxytocin Trial in Prader-Willi Syndrome

NCT02013258
View directory record Official record
Conditions
Prader Willi Syndrome
Interventions
Intranasal oxytocin, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
5 Years to 11 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
3
States / cities
Orange, California • Gainesville, Florida • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Sep 30, 2026, 10:47 AM EDT
Completed Phase 1 Interventional

Probiotics and Oxytocin Nasal Spray on Social Behaviors of Autism Spectrum Disorder (ASD) Children

NCT03337035
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
intranasal oxytocin, oral probiotics, oral placebo
Drug · Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
3 Years to 25 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Sep 30, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

Intranasal Oxytocin for the Treatment of Alcohol Use Disorder

NCT03878316
View directory record Official record
Conditions
Alcohol Use Disorder, Alcohol Misuse
Interventions
Instranasal Oxytocin
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Sep 30, 2026, 10:47 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pilot Study of Pharmaceutical and Behavioral Interventions to Treat Anxiety Disorders

NCT01631682
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Anxiety Disorder
Interventions
Propranolol, Reactivation, Mifepristone, Intranasal oxytocin
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 35 Years
Enrollment
186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Sep 30, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

Piloting Treatment With Intranasal Oxytocin in Phelan-McDermid Syndrome

NCT02710084
View directory record Official record
Conditions
Phelan-McDermid Syndrome
Interventions
Oxytocin, Saline
Drug
Lead sponsor
Alexander Kolevzon
Other
Eligibility
5 Years to 17 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Sep 30, 2026, 10:47 AM EDT